Browse by author
Lookup NU author(s): Professor Graham Jackson
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
We have sequenced 463 presenting cases of myeloma entered into the UK Myeloma XI study using whole exome sequencing. Here we identify mutations induced as a consequence of misdirected AID in the partner oncogenes of IGH translocations, which are activating and associated with impaired clinical outcome. An APOBEC mutational signature is seen in 3.8% of cases and is linked to the translocation- mediated deregulation of MAF and MAFB, a known poor prognostic factor. Patients with this signature have an increased mutational load and a poor prognosis. Loss of MAF or MAFB expression results in decreased APOBEC3B and APOBEC4 expression, indicating a transcriptional control mechanism. Kataegis, a further mutational pattern associated with APOBEC deregulation, is seen at the sites of the MYC translocation. The APOBEC mutational signature seen in myeloma is, therefore, associated with poor prognosis primary and secondary translocations and the molecular mechanisms involved in generating them.
Author(s): Walker BA, Wardell CP, Murison A, Boyle EM, Begum DB, Dahir NM, Proszek PZ, Melchor L, Pawlyn C, Kaiser MF, Johnson DC, Qiang YW, Jones JR, Cairns DA, Gregory WM, Owen RG, Cook G, Drayson MT, Jackson GH, Davies FE, Morgan GJ
Publication type: Article
Publication status: Published
Journal: Nature Communications
Year: 2015
Volume: 6
Online publication date: 23/04/2015
Acceptance date: 24/03/2015
ISSN (electronic): 2041-1723
Publisher: Nature Publishing Group
URL: http://dx.doi.org/10.1038/ncomms7997
DOI: 10.1038/ncomms7997
Altmetrics provided by Altmetric